The Liver Meeting

The Liver Meeting

November 10, 2014
2 min read

High SVR achieved with ledipasvir/sofosbuvir plus ribavirin after transplant

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

BOSTON — Twelve or 24 weeks of treatment with ledipasvir and sofosbuvir plus ribavirin yielded sustained virologic response rates higher than 90% in patients with hepatitis C virus recurrence after liver transplantation, according to data presented at The Liver Meeting.

The prospective, multicenter study included 223 patients with HCV genotype 1 and 4 infection who had a liver transplant. All received treatment with ledipasvir 90 mg per day and sofosbuvir 400 mg per day plus ribavirin for 12 (n=112) or 24 weeks (n=111). The primary endpoint was SVR 12 weeks after completion of study treatment.

Recently, “ledipasvir and sofosbuvir have been coformulated into a single tablet taken once daily,” K. Rajender Reddy, MD, from the University of Pennsylvania School of Medicine, said during a presentation. The combination treatment is marketed as Harvoni (Gilead).

The analysis included both treatment-naive and treatment-experienced patients. Other inclusion criteria included fibrosis stage F0 to F3 (n=111); Child-Pugh-Turcotte (CPT) class A (n=51), B (n=52) and C (n=9) with cirrhosis; and estimated glomerular filtration rate greater than 40 mL/min.

“The study had broad inclusion criteria,” Reddy said. “Patients had to have been at least 3 months out from liver transplant. Patients with hepatocellular carcinoma were excluded.”

During a presentation, Reddy reported ribavirin dose escalation for patients with CPT class B and C and weight-based regimen for those with F0 to F3 fibrosis and CPT class A cirrhosis.

Median time from transplant to treatment was 2.9 to 8.1 years.

SVR12 among patients with F0 to F3 fibrosis was 96% for those who received 12 weeks of treatment and 98% for 24 weeks of treatment.

Among patients with CPT class A, SVR12 was 96% for 12 and 24 weeks of treatment. Among patients with CPT class B, SVR12 was 85% for those who received 12 weeks of treatment and 83% for 24 weeks of treatment. Among those with CPT class C, SVR12 was 60% for those who received 12 weeks of treatment and 67% for 24 weeks of treatment, Reddy said during a session.

“There were six relapses among the 223 patients in the study,” Reddy said.

Seven patients died and two withdrew consent. There were no on-treatment virologic failures or breakthroughs, according to Reddy.

More patients with CPT class B demonstrated improvement in MELD score compared with patients with CPT class A. Eighteen patients had unchanged MELD scores, Reddy said.

In other findings, the researchers observed a significant decrease in bilirubin, regardless of treatment duration, and a significant improvement in albumin in all groups.

Anemia and portal vein thrombosis were the most commonly reported adverse events. While most patients experienced an adverse event, grade 3 or 4 events were uncommon. “These events did not appear to be related to longer duration of therapy,” he said.

“In patients with recurrent HCV post-transplantation, treatment with ledipasvir and sofosbuvir with ribavirin was associated with high rates of SVR regardless of disease severity or duration of therapy,” Reddy concluded. – by Rob Volansky

For more information:

Reddy KR. Abstract 8. Presented at: The Liver Meeting; Nov. 7-11, 2014; Boston.

Disclosure: Reddy reports serving on advisory committees/review panels for AbbVie, Bristol-Myers Squibb, Genentech/Roche, Gilead, Janssen, Merck, Novartis and Vertex, and grant/research support from AbbVie, Bristol-Myers Squibb, Gilead, Ikaria, Janssen and Merck. See the abstract for the other researchers’ relevant financial disclosures.